Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05328986 · ClinicalTrials.gov registry record
Kidney Disease After COVID-19
A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 1,753
- Enrollment target
NCT05328986: Completed study, sponsored by Icahn School of Medicine at Mount Sinai.
NCT05328986 is a clinical trial that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 1,753 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05328986 has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 1,753 participants
- Enrollment target
Study Summary
To understand the long-term epidemiology, develop effective risk-prediction and stratification tools, and understand the pathobiology of kidney disease in COVID-19 survivors.
Primary Outcome
Kidneys filter blood by removing waste and extra water to make urine. The kidney's filtration rate, called the glomerular filtration rate (GFR), shows how well the kidneys are filtering. A normal GFR is 60 or higher.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,753 participants |
| Start Date | 2020-01-04 |
| Est. Completion | 2024-01-04 |
What the finished NCT05328986 record still lists
NCT05328986 is an observational study that tracks outcomes without assigning an intervention. Its 1,753 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05328986 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05328986 about?
NCT05328986 is a clinical study titled "Kidney Disease After COVID-19". To understand the long-term epidemiology, develop effective risk-prediction and stratification tools, and understand the pathobiology of kidney disease in COVID-19 survivors.
What is the current status of trial NCT05328986?
This trial is currently completed. The enrollment target is 1,753 participants. The study started on 2020-01-04. Estimated completion is 2024-01-04.
Who is sponsoring clinical trial NCT05328986?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07062172 · 1,753 participants · NA
Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer
- NCT06872892 · 1,755 participants · Phase 3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
- NCT05934487 · 1,750 participants · NA
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
- NCT06954337 · 1,750 participants · NA
MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI